T h e W o r k : P rofessional A dvertising When treating Intervene now with Visudyne therapy and preserve vision long-term • Visudyne-treated patients retained more visual acuity over 3 years than untreated patients did in 3 months" •h patents with (rtdomnrc* ci*s« st*foeii CW aondaor tt ege-reiated macular degeneration Reference!: I ttrteporfin therapj far subfoeat chcradai newssoJanaticn m age-reiated macular degereratcn. Thrie-year resets zf an open-tabei u&acn of 2 randomized dnical trab. UP Report 5. Jfdi OcMhM 20D2.12O.1307-131*. verteporfin Central to sight in CNV www.visudyne.com N O V A R T IS OrHIIIAlMICS Pmatatfw: fanfcr tor saMontor edusoa iteft cortans IS mg vcneporte and t* t i t o w dmynstoyt pfosttoMA^tine. egg phojfhatidytglywrri, asosrbyf palmate, buttled tr/dnwylduene and lactose. ( M s : 1 ttal per padoge. Indication: 'risud/ne s rdcated for the treatment of patents predonnarCy etesc sjcfoea.' cnwidal ne^-asoiinssion due to age-related mactfar degeneration cr with tabfoveal ctoradal rewasci/arisatizn secondary t: pathotogeai myopia. Dosage: Step I: iifusicn of 6 mg verteporfh per m2 bod) Sixtjce dissaved r 30 mt 5H gixcse far ryec&an m r a period of t l -rejtes Step 2.15 mrutES after the start of f e infusion, exfcsure of 50 J/cm2 d red Ight (689 rm) onto (he choroidal neovaseutstumover a pericd of f3 seccnds wth an apprcpnate bser deifee Treaarent shod; be repeated eiery 3 rarts t CXi eeog* n a n . C«rtr*«ii6cat)ons: Knom hypersensfcwty to verteporth or to any ccrrprrent of the formulation In patients with severe hepatic impairment or porptr/ria PtecauticnsAVamrgs: Patents must avoid e«jx®Jt to drect sirfi^t cr irght ndcor igft ter 48 hous after S* haCaert Vsudjne therapy shodd be ccnstfered crefuly r pabests wtr nwferete hfpate rparment end Wlary otetoctlcn. Patients who erperfence a severe decrease of vision (4 Ines or mere) withn one wetk shxid rot beretraced untithor man ctnpeWi recawn to vt-ttmttt level r eitrawsatsn occurs, nfusen jheutt be stewed rrmedeteb Die affected area must be thorough!) crootcted from cirecl light untl swUng and deco’orabcn ta e dtappeaied Cdd cempress* sfaUd be (laced os the ryecaon see and m l g t » may be gm i accessary. Wndyae te np y trder general anesthesia shoJd be considered with cajson. There are r» cJnical data to srpport a corccrntant treatment of the second eye. However, if the treatment b deemed necessary, Ight stodd be appied 'a t* secend eye m e te e fy adeer Ig ft apciaton eithefirseyebicnobterdun20 mirutes from the start cf the rfiaioa Interacbons: Conromtant treatment with other ptotoserati/ing agents may i-crease (holcisensitwityreactions. Undesirableeffects (DM and Htfm) Ocubr see effects, tener-a' man such as btny. hazy, fuzzy van y flashes of light. decreased wsim, roual field defect such as grey cr dart haloes, scotoma ard Mac* spots retinal detachment (ncrrhegmalogenous). ajbretinal hemorrhage, litrous femcrrhage. kyectun its aje effects Par, ederu. ecraiasxm. rffammaam hera-hage. fiypenerstnity. dscdcratin. Systemic side effKts: Kaxea, phrtnsensitMty reaefcns, Wusico-relarted pain pri-rarif/ presenting as back pan, tut may abo radiate to oter areas such as the 1. AGENCY: WPP Grey Healthcare CREATIVE TEAM: Dan Schiolto, Karin Mikshe, Jodi Sholinski CLIENT: Cytyc 2. AGENCY: Euro RSCG Life MetaMax CREATIVE TEAM: Chet Moss, Lori Spielberger CLIENT: Novartis 191
RkJQdWJsaXNoZXIy NDMwNDAx